[go: up one dir, main page]

WO1999047553A2 - Famille de polypeptides bacteriens - Google Patents

Famille de polypeptides bacteriens Download PDF

Info

Publication number
WO1999047553A2
WO1999047553A2 PCT/GB1999/000850 GB9900850W WO9947553A2 WO 1999047553 A2 WO1999047553 A2 WO 1999047553A2 GB 9900850 W GB9900850 W GB 9900850W WO 9947553 A2 WO9947553 A2 WO 9947553A2
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
amino acid
iii
antagonist
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1999/000850
Other languages
English (en)
Other versions
WO1999047553A3 (fr
Inventor
Fabrizio Arigoni
Michael David Edgerton
Hannes Loferer
Manuel C. Peitsch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to JP2000536744A priority Critical patent/JP2002506628A/ja
Priority to EP99910541A priority patent/EP1064301A1/fr
Priority to AU29473/99A priority patent/AU2947399A/en
Publication of WO1999047553A2 publication Critical patent/WO1999047553A2/fr
Anticipated expiration legal-status Critical
Publication of WO1999047553A3 publication Critical patent/WO1999047553A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • This invention relates to a family of bacterial polypeptides which are required for growth of both gram negative and gram positive bacteria, the genes which encode them and the use of such polypeptides and genes as tools for identifying novel broad spectrum antibiotics.
  • the invention therefore provides an isolated polypeptide of the yaeL family as defined below particularly for use in the identification of novel antibiotic agents.
  • polypeptides of the present invention are believed to be essential to the viability of a wide range of bacteria including both gram positive and gram negative bacteria.
  • BLAST searches J. Mol. Biol. (1990) 215:403 -10 and Meth. Enzymol. (1996) 266: 131-141 , 227-258 both incorporated herein by reference
  • Such searches involve using in succession as query sequences, each of the existing yaeL protein family member sequences to identify other full length members of the yaeL family of proteins.
  • HSP high-scoring segment pairs
  • Profile based searches may be carried out using position-dependent scoring matrices defined for the yaeL family members. These searches use a table compiled from a multiple sequence alignment which describes distinctive sequences of amino acids as probability values for each residue at each position in the gene family to identify other proteins which contain similar sequences of amino acids.
  • Motif based searches may be carried out using PROSITE patterns defined for the yaeL family members. These searches involve the representation as patterns, of the conserved sequence elements identified in the profile searches.
  • the isolated polypeptides of the invention may therefore be characterised by:
  • HSP score of greater than or equal to 250 when compared with one of the sequences of Figure 1 when the BLAST algorithm is used with a BLOSUM62 scoring matrix ;
  • X is any one amino acid residue, and the numbers in the curved brackets refer to the number of residues at that position; or
  • X is any one amino acid residue, and the numbers in the curved brackets refer to the number of residues at that position.
  • the invention also provides an isolated polypeptide sequence as set out in any of Figures 2a-d.
  • polypeptides are preferably recombinant and ideally purified to homogeneity.
  • polypeptides according to the invention are variants, analogues and derivatives. Particularly those in which a number of amino acids have been substituted, deleted or added.
  • Polypeptides which have at least 70% identity to any of the polypeptide sequences according to the invention, in particular the sequences of Figures 2a-d are encompassed within the invention.
  • the identity is at least 80%, more preferably at least 90% and still more preferably at least or greater than 95% identity for example 97%, 98% or even 99% identity to any of the sequences according to the invention, in particular the sequences of Figures 2a-d.
  • Such polypeptides may also be fragments.
  • a fragment is a part of a polypeptide according to the invention which retains sufficient identity of the original polypeptide to be effective for example in a screen.
  • Such fragments may be fused to other amino acids or polypeptides or may be comprised within a larger polypeptide.
  • Such a fragment may be comprised within a precursor polypeptide designed for expression in a host. Therefore in one aspect the term fragment means a portion or portions of a fusion polypeptide or polypeptide derived from a polypeptide according to the invention.
  • Fragments also include portions of a polypeptide according to the invention characterised by structural or functional attributes of a polypeptide according to the invention.
  • fragments may comprise an alpha helix or alpha -helix forming region, beta sheet and beta-sheet forming region, turn and turn forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, amphipathic regions (alpha or beta), flexible regions, surface-forming regions, substrate binding regions and regions of high antigenic index.
  • Fragments or portions may be used for producing the corresponding full length polypeptide by peptide synthesis.
  • polypeptides according to the invention include the polypeptides of Boirella burgdorferi, Treponema pallidium, Synechocystis sp. Strain PCC6803, Helicobacter pylori, Arabidopsis thaliana, Haemophilus influenza, Pseudomonas aeruginosa, Streptococcus pneumoniae, Streptococcus pyogenes, Bacillus subtilis and Escherichia coli.
  • the present invention further provides isolated polynucleotides which encode the polypeptides as defined herein, polynucleotides complementary thereto, or polynucleotides hybridising to any of the aforesaid polynucleotides.
  • Isolated polynucleotides have been removed by separation from their natural environment and those materials with which they are naturally associated.
  • these polynucleotide molecules are provided in recombinant form (i.e. combined with one or more heterologous sequences).
  • stringent hybridisation conditions which is sometimes used is where attempted hybridisation is carried out at a temperature of from about 35°C to about 65°C using a salt solution which is about 0.9 molar.
  • the skilled person will be able to vary such conditions as appropriate in order to take into account variables such as probe length, base composition, type of ions present, etc.
  • the invention also provides polynucleotide variants, analogues, derivatives and fragments which encode polypeptides according to the invention.
  • Polynucleotides are included which preferably have at least 70% identity over their entire length to a polynucleotide encoding a polypeptide according to the invention, most preferably those set out in Figures 2a-d. More preferred are those sequences which have at least 80% identity over their entire length to a polynucleotide encoding a polypeptide according to the invention. Even more preferred are polynucleotides which demonstrate at least 90% for example 95%, 97%, 98% or 99% identity over their entire length to a polynucleotide encoding a polypeptide according to the invention.
  • Polynucleotide molecules of the present invention may be used as probes for other members of the gene family or in anti-sense therapy to block or to reduce the expression of one or more of the polypeptides of the invention. Since these substances are believed to be essential to the bacteria expressing them, blocking or reducing their expression can provide an effective way of treating bacterial mediated diseases or disorders. Polynucleotides may also be used directly in screening and in generating whole cell screens by expression of a polypeptide of the inventions.
  • the polynucleotides may be joined to other polynucleotides such as to form fusions or to regulatory elements for expression.
  • Isolated polynucleotides alone or joined to other polynucleotides can be in introduced into a vector which itself will contain other elements of DNA or RNA for expression in a host cells.
  • the invention therefore comprises a vector containing a polynucleotide generally operatively linked to appropriate expression control sequences.
  • Vectors for use in the invention include plasmid vectors, phage vectors and DNA or RNA viral vectors.
  • These vectors may include gene sequences which render them inducible under certain conditions such as manipulation of the environmental conditions under which the host cells are maintained for example by temperature alteration or nutrient additives.
  • Regulatory sequences include for example a promoter to direct mRNA transcription.
  • promoters include for example E.Coli. lac, trp, tac and araBAD as well as the SV40 early and late promoters Such systems and sequences would be well known to those skilled in the art.
  • Host cells expressing a polynucleotide of the present invention can be generated by any of the traditional routes such as transfection or electroporation see for example Davis et al, Basic Methods in Molecular Biology, (1986) and Sambrook et al Molecular Cloning: A Laboratory Manual, 2 nd Edition., Cold Spring Harbor Lab. Press, Cold Spring Harbor, N.Y. (1989).
  • This invention also provides a method for identification of molecules such as antagonists, that bind to the polypeptide or a polynucleotide encoding a polypeptide of the present invention.
  • Biochemical assays for inhibition of polypeptide activity with purified polypeptides or bacterial extracts can be more sensitive than whole cell killing assays and provide direct evidence for a compound's mode of action.
  • this approach requires that the target polypeptide is known and the activity of the polypeptide be amenable to in vitro assays. Nor does it address other factors, such as membrane permeability or compound stability, which can limit a compounds effectiveness as an antibiotic.
  • Whole cell screening of compounds for killing activity will identify molecules which kill cells at the concentrations tested, but provide no information on the mode of action of the compound and may not have the sensitivity needed to detect less potent compounds.
  • Bacterial strains which contain surrogate markers whose activity is linked to that of the target gene or which have been engineered to over-express or under-express the target polypeptide can be used for selective whole-cell screens.
  • the invention further provides a host cell comprising a vector as defined herein and a reporter gene encoding a reporter molecule whose activity is linked to that of the polypeptide encoded by the vector.
  • a reporter gene encoding a reporter molecule whose activity is linked to that of the polypeptide encoded by the vector. Examples of such systems include a transcriptional fusion of the E. coli lacZ gene to vanH promoter in a B. subtilis strain expressing VanS and R as a reporter for inhibition of cell wall biosynthesis (J. Bacteriol.
  • surrogate markers for the activity of the gene can be identified using at least two approaches. Two dimensional elecfrophoresis coupled with mass spectrometry analysis of isolated polypeptides, proteome mapping, has been used to identify specific polypeptides which increase in abundance in response to polypeptide or RNA synthesis inhibitors (Microbial & Comparative Genomics (1996) 1:375). Tightly regulated promoters used to demonstrate that the E. coli and B. subtilis conserved, essential polypeptides are essential can also be used to reduce the concentrations of these polypeptides.
  • proteome maps generated from bacteria depleted of the conserved essential genes can be used to detect polypeptides which change in abundance as compared to wild-type bacteria. Transcriptional or translational fusions to these polypeptides can be used as reporter molecules to screen for antagonists of members of the conserved essential gene family.
  • fransposons or other mobile genetic elements containing reporter genes can be used to search for reporter molecules. Such an approach has been used to identify vancomycin responsive genes in S. aureus (Antibiot. (Tokyo) (1991) 44:210-217).
  • bacteria in which conserved essential genes are controlled by tightly regulated promoters can be used to screen for transposon carrying strains in which expression of promoterless reporter genes is induced upon depletion of the polypeptides.
  • Standard broth or plate assays can be used in many different formats. Such assays will detect molecules which antagonise the response which couples the activity of the conserved, target polypeptide to the reporter molecule. Thus, the compounds identified may act directly upon the target polypeptide or on another stage in the pathway which leads to activation of the reporter.
  • Screens for inhibitors of the target which do not require the use of surrogate markers may be designed by manipulating expression levels of the target polypeptide.
  • quinolone resistant strains of E. coli have been made by over-expression of gyrA (FEMS Microbiol. Lett. (1997) 154:271-276)
  • over-expression of alanine racemase has been shown to increase resistance to cycloserine in M. smegmatis
  • multicopy plasmids carrying murZ have been shown to increase phosphomycin resistance in both E. coli (J. Bacteriol. (1992) 174:5748-5752) and A. calcoaceticus (FEMS Microbiol.
  • strains more sensitive to antibiotics may be made by reducing expression levels of the polypeptide targeted by the antibiotic.
  • Over or under-expression of members of the conserved, essential gene family may be used to screen for antibiotics which act either directly on gene or gene product or indirectly on the pathway which it is involved.
  • Another example of an assay for antagonists is a competitive assay that combines the polypeptide of the present invention and a potential antagonist with membrane-bound binding molecules, recombinant binding molecules, natural substrates or Iigands, or substrate or ligand mimetics, under appropriate conditions for a competitive inhibition assay.
  • the polypeptide can be labelled, such as by radioactivity or a colorimetric compound, such that the number of polypeptide molecules bound to a binding molecule or converted to product can be determined accurately to assess the effectiveness of the potential antagonist.
  • the present invention therefore provides a method of assaying compounds for activity against bacteria comprising:
  • the present invention also provides a method of assaying compounds for activity against bacteria comprising:
  • the present invention further provides a method of screening for an antibiotic which method comprises:
  • the method may be carried out as above but the level of expression of the polypeptide is decreased and the cells are assayed for increased sensitivity to an inhibitor.
  • the present invention also provides a method of assaying compounds for activity against bacteria comprising:
  • Potential antagonists include small organic molecules, ions which interact specifically with a polypeptide or polynucleotide for example a substrate, cell membrane component, receptor a fragment thereof or a peptide.
  • Such molecules may include antibodies, antibody-derived reagents or chimaeric molecules.
  • Potential antagonists also may be small organic molecules, a peptide, a polypeptide such as a closely related protein or antibody that binds to the same sites on a binding molecule without inducing functional activity of the polypeptide of the invention.
  • the antibodies may be monoclonal or polyclonal. Techniques for producing monoclonal and polyclonal antibodies which bind to a particular polypeptide are now well developed in the art. They are discussed in standard immunology textbooks, for example in Roitt et al (Immunology, Churchill Livingston, 2nd Edition (1989)).
  • the present invention covers variants thereof which are capable of binding to an epitope present or a substance of the present invention.
  • the variants may be antibody fragments or synthetic constructs. Examples of antibody fragments and synthetic constructs are given by Dougall et al in Tibtech 12 372-379 (September 1994).
  • Antibody fragments include Fab and Fv fragments.
  • CDR peptides include CDR peptides. These are synthetic peptides comprising antigen binding determinants. Peptide mimetics may also be used.
  • humanised antibodies or derivatives thereof are within the scope of the present invention.
  • An example of a humanised antibody is an antibody having human framework regions, but a rodent or other non-human hypervariable regions.
  • Synthetic constructs also include molecules comprising a covalently linked moiety which provides the molecule with some desirable property in addition to antigen binding.
  • the moiety may be a label (e.g. a fluorescent or radioactive label) or a pharmaceutically active agent
  • antisense molecules see Okano, J. Neurochem. 56:560 (1991); Oligodeoxynucleotides As Antisense Inhibitors Of Gene Expression, Crc Press, Boca Raton, FL (1988), for a description of these molecules).
  • the invention provides the use of the polypeptide, polynucleotide or antagonist of the invention to interfere with the initial physical interaction between a pathogen and mammalian host responsible for sequelae of infection.
  • the invention further includes molecules which block the function of the polypeptides according to the invention or a polynucleotide encoding the same, identifiable by any of the above described methods.
  • An antagonist of the invention may be provided in pharmaceutical compositions which may include a carrier. They may be provided in unit dosage form. Such agents and pharmaceutical compositions are within the scope of the present invention. In order to prepare such pharmaceutical compositions the inhibitors will normally be provided in substantially pure form. They can then be combined with a carrier under sterile conditions.
  • the present invention also provides a method of treatment which comprises administering to a patient an effective amount of an antagonist of the expression or function of a polypeptide as defined herein.
  • the present invention further provides the use of an antagonist of a polypeptide as defined herein or a polynucleotide encoding the same for the manufacture of a medicament for the treatment of a bacterial infection.
  • Figure 1 shows the multiple sequence alignment and BLAST based identification of the yaeL family members.
  • Figures 2a-d show sequence alignments of the yaeL family members.
  • Figure 3 shows the PROSITE patterns based on the motifs generated from the position dependent scoring matrices.
  • Figure 4 shows the outline cloning strategy for a gene disruption plasmid.
  • the black box represents the adaptor sequence.
  • Figure 5 shows Growth dependence on arabinose of a conditional mutant in the E.coli gene yaeL.
  • Figure 6 Is a diagram of the vector used to create conditional mutants in B. subtilis.
  • Figure 7 shows growth dependence on xylose of a conditional mutant in the B. subtilis yaeL orthologue yluC
  • Seq ID No. 4 and Seq ID No. 5 are respectively elements of a single sequence and are separated from each other by 30-40 Xaa residues, where each Xaa is any one amino acid.
  • Example 1 Identification of conserved bacterial open reading frames.
  • the SIM score was then divided by a "selfSIM” score, a value obtained when the query protein is compared to itself using SIM algorithm with the PAM200 matix, to yield a similarity value of between 1.0 and 0. Proteins for which this similarity value was greater than 0.2 when the E. coli protein was compared to either the B. subtilis or M. genatilum genome where then compiled into a list and manually screened to identify proteins of unknown function. Those open reading frames which also had high similarity values in other bacteria were then considered as candidate genes and targets for gene disruption.
  • a disruption plasmid was constructed using DNA containing an in-frame deletion of the gene of interest plus -900 base pairs of 5' and 3' flanking DNA for homologous recombination.
  • the plasmid was cloned into the gene- replacement vector pKO3 as follows: Two separate PCR reactions were used to amplify fragments of approximately 900 base pairs of 5' and 3' sequence flanking the gene of interest. Chromosomal DNA from E.coli strain MG1655 was used as the template. Primers 2 and 3 carry a 5' extension of a 33 bp adaptor sequence
  • the 2 PCR products were purified using High PureTMPCR Product Purification Kit (Boehringer Mannheim Inc., Mannheim, GE). Using the adaptor sequence, the 2 PCR products are assembled in a second PCR reaction to give a single product . Following restriction enzyme digestion, preparative agarose gel elecfrophoresis and purification using JetsorbTMGel Extraction Kit (Genomed Inc.) the final product was cloned into pKO3 using standard techniques. This clone is referred to as the disruption plasmid. All PCR reactions described in this section were performed with PWOTM DNA Polymerase (Boehringer Mannheim Inc., Mannheim, GE).
  • the gene of interest was deleted from the start to the stop codon and replaced by the 33 bp adaptor sequence [e.g. 5'- ATGgttataaatttggagtgtgaaggttattgcgtgTAA-3']. As a consequence the reading frame is maintained.
  • the disruption vector pKO3 (A.J.Link et al., J. Bacteriol. 179:6228-6237,1997) is a derivative of pMAK700 (C.A.Hamilton et al., J. Bacteriol. 171:4617-4622). It features the repA (Ts) replication origin derived from pSC101 [permissive at 30°C but inactive at 42 to 44°C], the cat gene encoding chloramphenicol resistance and the sacB gene for counter selection against vector sequences in the presence of 5% sucrose.
  • chromosomal integrates (cointegrates produced by a single homologous recombination event) of the plasmid were isolated by selecting clones on chloramphenicol at 44°C. Following 2-times purification under the same conditions, the cointegrates are grown at 30°C in the presence of 5% sucrose to force resolution of the cointegrate and elimination of the plasmid from the cell. At this step, a preliminary assignment if a given gene is essential or non-essential for growth of E.coli in complex media was made.
  • the genotype of the chloramphenicol-sensitive clones obtained following cointegration and resolution of the disruption plasmid was determined by colony-PCR using primers d and c2 (see Fig.4).
  • the second recombination event can result in either a wild-type or a mutant genotype.
  • the testing of 20 independent clones showed routinely that a ⁇ 1 :1 distribution of wild-type versus mutant genotype in case of a non- essential gene. Recovery of only wild-type genotype in 50 independent clones was considered as preliminary evidence for a gene's essentiality.
  • pRDC15 was designed, which allows a copy of a putative essential gene to be placed in ectopic position on the chromosome under the control of a tightly regulated promoter.
  • the plasmid is a derivative of pKO3.
  • pRDC15 carries a DNA fragment consisting of the araC gene, the arabinose promoter, a cloning site [Bam ⁇ -Nhe ⁇ -Sfi ⁇ -Xho ⁇ -Sph ⁇ -Sfil] and the polB gene.
  • the wild-type copy of a putative essential gene was amplified by PCR and cloned into the vector pRDC15 using restriction sites Nhe ⁇ and Xho ⁇ .
  • the resulting construct was used for gene replacement in a manner identical to the disruption plasmids described above.
  • the araC and polB genes of pRDC15 represent the homologous DNA for recombination at the araCBADpolB locus of the E.coli chromosome.
  • the araBAD genes in the E.coli chromosome are replaced by the wild-type copy of the gene of interest, which is now under the control of the arabinose promoter.
  • This merodiploid strain is then used to construct an in frame deletion of the wild-type target gene using the disruption plasmid described above in the presence of 0.2% arabinose.
  • the deletion mutant can be obtained since a wild-type copy is expressed in trans from the arabinose locus.
  • the resulting strain is a conditional mutant as expression of the target gene is now dependent on the presence of arabinose.
  • the inability of such a strain to grow in the absence of arabinose is a final proof that a given gene is essential for growth of E.coli.
  • Figure 5 shows the example of the putative metalloprotease gene yaeL
  • Example 3 yluC is an essential gene in Bacillus subtilis.
  • An integrative plasmid allowing the expression of genes under the control of a xylose inducible promoter was constructed as follows: A DNA fragment carrying the repressor gene xylR and the xylA promoter was PCR amplified from B. subtilis genomic DNA with the following primers: pxyl-4: 5'-atcgctcgagAGATGCACCTTCTATACCCG-3' pxyl-7: 5'-atcgaagcttAGCGATCCTACACAATCATG-3'
  • the primers were designed such that they introduced a unique EcoRI site at the 5' end of the PCR product and a unique Bam ⁇ site at the 3' end of the product.
  • the PCR fragment was then cloned as an EcoR ⁇ -BamHI fragment into the B. subtilis integrative vector pDG648 to yield pRDC9 ( Figure 6).
  • a DNA fragment containing the 5' region of yluC was amplified by PCR from B. subtilis genomic DNA with the following primers:
  • pYluC-1 5'-agctaagcttcaatactcacataaggtggt-3'
  • pYluC-2 5'-tgcactcgaggcatgcattggcgattatacggcgca-3'
  • the primers were designed such that the resulting PCR product contains unique Hind W site at the 5' end of the PCR product and a unique Sph ⁇ site at the 3'end. Subsequently, the PCR product was digested with H ⁇ dlll and Sph ⁇ and cloned into the HindlW and Sphl sites of pRDC9.
  • the disruption plasmid was inserted into B. subtilis strain JH642. Chromosomal integration of the plasmid via single-reciprocal Campbell-like recombination at the yluC locus into the chromosome was driven by selection on LB plates containing erythromycin (1 ⁇ g/ml), lincomycin (25 ⁇ g/ml) and 10 mM xylose. The resulting strain is a conditional mutant in which expression of yluC is dependent on the presence of xylose into the growth medium.
  • P. aeruginosa - Contig203 from Pseudomonas aeruginosa genome sequencing project http://www.pseudomonas.com/). September 15, 1997 data release.
  • MAST motif alignment and search tool
  • yaeL family members which are positively identified when p-values of less than 1 x 10 "30 are obtained.
  • p-values are based on a random sequence model that assumes each position in a random sequence is generated according to the average letter frequencies of all sequences in the peptide non-redundant database (ftp://ncbi.nlm.nih.gov/blast/db/) on September 22, 1996.
  • Tables 1 to 4 show the position dependent scoring used to define the yaeL family. Values in the position-dependent scoring matrix are calculated by taking the log (base 2) of the ratio p/f at each position in the motif where p is the probability of a particular letter at that position in the motif, and f is the average frequency of that letter in the training set. Columns correspond to 1 letter amino acid codes and rows correspond to the position in the motif.
  • PROSITE patterns using the conventions outlined in PROSITE: A dictionary of protein sites and patterns (http://www.expasy.ch/sprot/prosite.html) and Bairoch A., Bucher P., Hofmann K. The PROSITE datatase, its status in 1995. Nucleic Acids Res. 24:189-196(1995). YaeL family members are positively identified when exact matches to two of the three prosite patterns pattern 1 , pattern 2 or pattern 3 as set out in Figure 3are found in the protein sequence.
  • yaeL family members can be identified using the longer pattern 4 as set out in figure 3, which takes into account the overlap of pattern 1 with PROSITE pattern PS00142 ([GSTALIVN]-x(2)-H-E-[LIVMFYW]-[DEHRKP]-H-x-[LIVMFYWGSPQ]) and the consistent spacing seen between patterns 1 and 3.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une famille de polypeptides bactériens de la famille des gènes yaeL. L'invention concerne également des gènes codant ces polypeptides, ainsi que l'utilisation de tels gènes et polypeptides comme outils d'identification de nouveaux antibiotiques à large spectre.
PCT/GB1999/000850 1998-03-18 1999-03-18 Famille de polypeptides bacteriens Ceased WO1999047553A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2000536744A JP2002506628A (ja) 1998-03-18 1999-03-18 細菌性ポリペプチドファミリー
EP99910541A EP1064301A1 (fr) 1998-03-18 1999-03-18 Famille de polypeptides bacteriens
AU29473/99A AU2947399A (en) 1998-03-18 1999-03-18 Bacterial polypeptide family

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9805792.0 1998-03-18
GBGB9805792.0A GB9805792D0 (en) 1998-03-18 1998-03-18 Bacterial polypeptide family

Publications (2)

Publication Number Publication Date
WO1999047553A2 true WO1999047553A2 (fr) 1999-09-23
WO1999047553A3 WO1999047553A3 (fr) 2001-02-22

Family

ID=10828810

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/000850 Ceased WO1999047553A2 (fr) 1998-03-18 1999-03-18 Famille de polypeptides bacteriens

Country Status (5)

Country Link
EP (1) EP1064301A1 (fr)
JP (1) JP2002506628A (fr)
AU (1) AU2947399A (fr)
GB (1) GB9805792D0 (fr)
WO (1) WO1999047553A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1043403A1 (fr) * 1999-04-09 2000-10-11 GPC AG, Genome Pharmaceuticals Corporation Méthode pour l'identification des composés antibactériens
WO2000061793A3 (fr) * 1999-04-09 2001-01-11 Gpc Biotech Ag Nouvelle methode d'identification de composes antibacteriens

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5552396A (en) * 1995-04-21 1996-11-07 Human Genome Sciences, Inc. Nucleotide sequence of the haemophilus influenzae rd genome, fragments thereof, and uses thereof
JP2001510989A (ja) * 1996-11-01 2001-08-07 スミスクライン・ビーチャム・コーポレイション 新規コーディング配列

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1043403A1 (fr) * 1999-04-09 2000-10-11 GPC AG, Genome Pharmaceuticals Corporation Méthode pour l'identification des composés antibactériens
WO2000061793A3 (fr) * 1999-04-09 2001-01-11 Gpc Biotech Ag Nouvelle methode d'identification de composes antibacteriens

Also Published As

Publication number Publication date
AU2947399A (en) 1999-10-11
EP1064301A1 (fr) 2001-01-03
GB9805792D0 (en) 1998-05-13
JP2002506628A (ja) 2002-03-05
WO1999047553A3 (fr) 2001-02-22

Similar Documents

Publication Publication Date Title
Buddelmeijer et al. Assembly of cell division proteins at the E. coli cell center
Gaspar et al. Bacillus anthracis sortase A (SrtA) anchors LPXTG motif-containing surface proteins to the cell wall envelope
Porter et al. The conjugation protein TcpC from Clostridium perfringens is structurally related to the type IV secretion system protein VirB8 from Gram‐negative bacteria
Van Staden et al. Functional expression of GFP-fused class I lanthipeptides in Escherichia coli
KR20010101861A (ko) 대장균 증식을 위한 유전자
Ocampo-Sosa et al. Demonstration of IS 711 transposition in Brucella ovis and Brucella pinnipedialis
KR20010033721A (ko) 필수 세균 유전자 및 이의 용도
WO1999047553A2 (fr) Famille de polypeptides bacteriens
CA2378796A1 (fr) Seripancrine
Readnour et al. Evolution of Streptococcus pyogenes has maximized the efficiency of the Sortase A cleavage motif for cell wall transpeptidation
WO1999054470A2 (fr) Famille de polypeptides bacteriens ygjd
US20030069398A1 (en) Identification of human gaba transporter
WO1999054462A2 (fr) Famille de polypeptides bacteriens ycfb
EP1073746A2 (fr) Famille de polypeptides bacteriens yjeq
WO1999054474A2 (fr) Famille de polypeptides bacteriens
Zhang et al. Elongation Factor Ts ofChlamydia trachomatis: Structure of the Gene and Properties of the Protein
US6706495B2 (en) Staphylococcal GTPase obg nucleotide sequence encoding Staphylococcal GTP-binding protein
CA2407893A1 (fr) Nouvelle proteine 1 activant la gtpase
WO2001009382A1 (fr) Antibiotique à base de protéines de lyse bactériophage
US7034125B2 (en) Identification of new human gaba transporter
CA2406195A1 (fr) Nouvelle proteine 4 de liaison des lipides
Caufield N-Terminal Processing of Ribosomal Protein L27 in Staphylococcus aureus
WO2001055428A2 (fr) Nouveaux composes
CA2400606A1 (fr) Nouveau type de phosphodiesterase 7b
WO2000014224A1 (fr) Genes putatifs codant pour les sous-unites gamma des canaux calciques commandes par potentiel des muscles du squelette

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999910541

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 09646273

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999910541

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWW Wipo information: withdrawn in national office

Ref document number: 1999910541

Country of ref document: EP